Recent Articles

RSS IP Licensing Law Blog

Raptor Pharmaceutical Signs License Agreement with Washington University

Written by on Tuesday, November 7th, 2006

Raptor Pharmaceutical Inc., an early stage biotechnology research and development company owned by Novato-based Raptor Pharmaceuticals Corp., has announced that it has signed an exclusive, worldwide license agreement with Washington University in St. Louis for the use of Mesd reagents for therapeutic treatment of cancer and osteoporosis.  Mesd  is a chaperone protein needed for the proper folding of the signal transduction receptors LRP5 and LRP6.

The St. Louis Business Journal reported that Raptor intends initially to test the potential of Washington University’s Mesd-based peptides for the treatment of cancer and osteoporosis, and that CEO of Rapto Pharmaceuticals Corp., Dr. Christopher Starr explained the agreement as follows:

"Mesd significantly adds to our growing franchise in the drug targeting area. . . . Mesd complements and extends our current programs and we believe will increase our reach and capabilities into a number of under-served disease indications with substantial market potential."



Category: Biotech Deals

Site search



RSS Software Law Blog

RSS Firm Events

© 2008-2018 The Prinz Law Office. All rights reserved.

The Prinz Law Office | Silicon Valley | Los Angeles | Orange County | San Diego | Atlanta | Tel: 1.800.884.2124

Silicon Valley Business Office: 2225 East Bayshore Rd., Suite 200, Palo Alto, CA 94304: Silicon Valley Mailing Address: 117 Bernal Rd., Suite 70-110, San Jose, CA 95119 Silicon Valley Office: (408) 884-2854 | Los Angeles Office: (310) 907-9218 | Orange County Office: (949)236-6777 | San Diego Office: (619)354-2727 | Atlanta Office: (404)479-2470

Licensed in California and Georgia.

Protected by Security by CleanTalk and CleanTalk Anti-Spam